Patents by Inventor Gabriele Matschiner
Gabriele Matschiner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11827681Abstract: The present invention relates to a novel library for the generation of muteins and to novel muteins derived from human lipocalin 2 (Lcn2, hNGAL) and related proteins that bind a given target with detectable affinity. The invention also relates to corresponding nucleic acid molecules encoding such a mutein and to a method for their generation. The invention further relates to a method for producing such a mutein. For example, such muteins may serve to bind and deplete pathological forms of natural biomolecules such as the amyloid beta peptide in Alzheimer's disease or may target the fibronectin extra-domain B, which is associated with tumor neovasculature.Type: GrantFiled: March 6, 2020Date of Patent: November 28, 2023Inventors: Arne Skerra, Michaela Gebauer, Dominik Hinz, Sabine Rauth, Gabriele Matschiner, Martin Huelsmeyer
-
Publication number: 20220193191Abstract: The present invention relates to the treatment of asthma in a human subject by administering by inhalation a therapeutically effective amount of an anti-IL-4 receptor alpha (IL-4Ra) lipocalin mutein, or a variant or fragment thereof, to said subject, wherein the delivered dose of said lipocalin mutein, or variant or fragment thereof, is from about 0.1 mg to about 160 mg. The lipocalin mutein, or a variant or fragment thereof, may for example be administered at least once per day, once per day or twice per day.Type: ApplicationFiled: March 25, 2020Publication date: June 23, 2022Inventors: Lena Therese AXELSSON, David Robert CLOSE, Philip GARDINER, Aulikki Ingergard Alexandra JAUHIANINEN, Ekaterina PARDALI, Mary FITZGERALD, Gabriele MATSCHINER, Ingmar BRUNS, Gunnel Marita OLSSON
-
Publication number: 20220168387Abstract: The present invention relates to inhaled administration of a lipocalin mutein to a subject, wherein the administration provides for local exposure to the lipocalin mutein in the respiratory tract. The present invention also relates to inhalative administration of a lipocalin mutein to a subject, wherein the administration provides for systemic exposure to the lipocalin mutein.Type: ApplicationFiled: March 27, 2020Publication date: June 2, 2022Applicant: PIERIS PHARMACEUTICALS GMBHInventors: Gabriele MATSCHINER, Ahmed MOUSA, Vanessa WELK, Gary ANDERSON, Christine WRIGHT, Thomas JAQUIN
-
Publication number: 20210196788Abstract: The present invention relates to novel muteins derived from human tear lipocalin, which bind to IL 4 receptor alpha. The sequences of the muteins comprise particular combinations of amino acids. In particular a mutated amino acid residue is present at any one or more of the sequence positions 27, 28 30, 31, 33, 53, 57, 61, 64, 66, 80, 83, 104-106 and 108 of the linear polypeptide sequence of the mature human tear lipocalin. A mutated amino acid residue is also present at any 2 or more of the sequence positions 26, 32, 34, 55, 56, 58 and 63 of the linear polypeptide sequence of the mature human tear lipocalin. The invention also provides a corresponding nucleic acid molecule encoding such a mutein and a method for producing such a mutein and its encoding nucleic acid molecule.Type: ApplicationFiled: December 16, 2020Publication date: July 1, 2021Inventors: Andreas HOHLBAUM, Alexandra Baehre, Gabriele Matschiner, Stefan Trentmann, Klaus Kirchfeld, Hans-Juergen Christian
-
Patent number: 11034737Abstract: The present disclosure provides hNGAL muteins that bind CGRP and can be used in various application including pharmaceutical applications, for example, migraine. The present disclosure also concerns methods of making one or more muteins described herein as well as compositions and combinations comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions and combinations comprising one or more of such muteins.Type: GrantFiled: July 8, 2019Date of Patent: June 15, 2021Assignee: Pieris Pharmaceuticals GmbHInventors: Gabriele Matschiner, Christine Rothe, Alexander Wiedenmann, Rachida Siham Bel Aiba, Marlon Hinner, Andrea Allersdorfer, Bradley Lunde, Kazufumi Kubota, Mitsuhiro Makino, Sakiko Takahashi, Ryuji Hashimoto, Tohru Takahashi, Mamoru Otoyo
-
Patent number: 10927154Abstract: The disclosure provides a multi-specific polypeptide with a first moiety specific for a tumor-associated antigen on tumor cell surface and a second moiety specific for an immune checkpoint protein, which multi-specific polypeptide can be useful for biasing a T-cell-mediated response to a tumor micro-environment. For example, the polypeptide may contain: a) a first binding domain, for example, a full-length antibody or an antigen-binding domain of an antibody, specifically recognizing a tumor-associated antigen on tumor cell surface, and b) a second binding domain, such as a lipocalin mutein, capable of stimulating T-cell proliferation e.g., by inhibiting a protein receptor that down-regulates the immune system. The first binding domain may be genetically linked (i.e., peptide bond at its N- or C-terminus) to the second binding domain. The multispecific polypeptide also may contain a third or yet additional specific binding moieties, any of which can specifically bind a distinct immune checkpoint protein.Type: GrantFiled: January 12, 2015Date of Patent: February 23, 2021Assignee: Pieris Pharmaceuticals GmbHInventors: Shane Olwill, Alexander Wiedenmann, Andrea Allersdorfer, Rachida Bel Aiba, Gabriele Matschiner, Bradley Lunde
-
Patent number: 10898545Abstract: The present invention relates to novel muteins derived from human tear lipocalin, which bind to IL 4 receptor alpha. The sequences of the muteins comprise particular combinations of amino acids. In particular a mutated amino acid residue is present at any one or more of the sequence positions 27, 28 30, 31, 33, 53, 57, 61, 64, 66, 80, 83, 104-106 and 108 of the linear polypeptide sequence of the mature human tear lipocalin. A mutated amino acid residue is also present at any 2 or more of the sequence positions 26, 32, 34, 55, 56, 58 and 63 of the linear polypeptide sequence of the mature human tear lipocalin. The invention also provides a corresponding nucleic acid molecule encoding such a mutein and a method for producing such a mutein and its encoding nucleic acid molecule.Type: GrantFiled: January 24, 2019Date of Patent: January 26, 2021Inventors: Andreas Hohlbaum, Alexandra Baehre, Gabriele Matschiner, Stefan Trentmann, Klaus Kirchfeld, Hans-Juergen Christian
-
Publication number: 20200308237Abstract: The present invention relates to a novel library for the generation of muteins and to novel muteins derived from human lipocalin 2 (Lcn2, hNGAL) and related proteins that bind a given target with detectable affinity. The invention also relates to corresponding nucleic acid molecules encoding such a mutein and to a method for their generation. The invention further relates to a method for producing such a mutein. For example, such muteins may serve to bind and deplete pathological forms of natural biomolecules such as the amyloid beta peptide in Alzheimer's disease or may target the fibronectin extra-domain B, which is associated with tumor neovasculature.Type: ApplicationFiled: March 6, 2020Publication date: October 1, 2020Inventors: Arne Skerra, Michaela Gebauer, Dominik Hinz, Sabine Rauth, Gabriele Matschiner, Martin Huelsmeyer
-
Patent number: 10787491Abstract: The present disclosure relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Glypican-3 (GPC3), which proteins preferably are muteins of a lipocalin protein, more preferably of lipocalin 2 (Lcn2 or NGAL). Present disclosure also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, present disclosure also is directed to pharmaceutical and/or diagnostic compositions comprising such lipocalin proteins, including uses of these proteins.Type: GrantFiled: April 19, 2019Date of Patent: September 29, 2020Assignee: Pieris Pharmaceuticals GmbHInventors: Marlon Hinner, Andrea Allersdorfer, Rachida Siham Bel Aiba, Michaela Aloe, Alexander Wiedenmann, Gabriele Matschiner, Martin Huelsmeyer
-
Publication number: 20200148733Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic polypeptides directed against the target of Swiss Prot Q16552 and novel, specific-binding therapeutic and/or diagnostic polypeptides directed against the target of Swiss Prot Q9NPF7. In addition, the present invention relates to novel, specific-binding therapeutic and/or diagnostic polypeptides directed against one or both of Swiss Prot Q16552 and Swiss Prot Q9NPF7. The invention also relates to nucleic acid molecules encoding such polypeptides and to methods for generation of such polypeptides and nucleic acid molecules. In addition, the invention is directed to compositions comprising the polypeptides, and therapeutic and/or diagnostic uses of these polypeptides.Type: ApplicationFiled: November 21, 2019Publication date: May 14, 2020Inventors: Marlon Hinner, Laurent Audoly, Martin Huelsmeyer, Kristian Jensen, Gabriele Matschiner, Shane Olwill, Alexander Wiedenmann, Andrea Allersdorfer
-
Patent number: 10618941Abstract: The present invention relates to a novel library for the generation of muteins and to novel muteins derived from human lipocalin 2 (Lcn2, hNGAL) and related proteins that bind a given target with detectable affinity. The invention also relates to corresponding nucleic acid molecules encoding such a mutein and to a method for their generation. The invention further relates to a method for producing such a mutein. For example, such muteins may serve to bind and deplete pathological forms of natural biomolecules such as the amyloid beta peptide in Alzheimer's disease or may target the fibronectin extra-domain B, which is associated with tumor neovasculature.Type: GrantFiled: December 15, 2016Date of Patent: April 14, 2020Assignee: Pieris Pharmaceuticals GmbHInventors: Arne Skerra, Michaela Gebauer, Dominik Hinz, Sabine Rauth, Gabriele Matschiner, Martin Huelsmeyer
-
Patent number: 10526384Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic polypeptides directed against the target of Swiss Prot Q16552 and novel, specific-binding therapeutic and/or diagnostic polypeptides directed against the target of Swiss Prot Q9NPF7. In addition, the present invention relates to novel, specific-binding therapeutic and/or diagnostic polypeptides directed against one or both of Swiss Prot Q16552 and Swiss Prot Q9NPF7. The invention also relates to nucleic acid molecules encoding such polypeptides and to methods for generation of such polypeptides and nucleic acid molecules. In addition, the invention is directed to compositions comprising the polypeptides, and therapeutic and/or diagnostic uses of these polypeptides.Type: GrantFiled: November 20, 2013Date of Patent: January 7, 2020Assignee: Pieris Pharmaceuticals GmbHInventors: Marlon Hinner, Laurent Audoly, Martin Huelsmeyer, Kristian Jensen, Gabriele Matschiner, Shane Olwill, Alexander Wiedenmann, Andrea Allersdorfer
-
Publication number: 20190338002Abstract: The present disclosure provides hNGAL muteins that bind CGRP and can be used in various application including pharmaceutical applications, for example, migraine. The present disclosure also concerns methods of making one or more muteins described herein as well as compositions and combinations comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules.Type: ApplicationFiled: July 8, 2019Publication date: November 7, 2019Inventors: Gabriele Matschiner, Christine Rothe, Alexander Wiedenmann, Rachida Siham Bel Aiba, Marlon Hinner, Andrea Allersdorfer, Bradley Lunde, Kazufumi Kubota, Mitsuhiro Makino, Sakiko Takahashi, Ryuji Hashimoto, Tohru Takahashi, Mamoru Otoyo
-
Publication number: 20190309037Abstract: The present disclosure relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Glypican-3 (GPC3), which proteins preferably are muteins of a lipocalin protein, more preferably of lipocalin 2 (Lcn2 or NGAL). Present disclosure also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, present disclosure also is directed to pharmaceutical and/or diagnostic compositions comprising such lipocalin proteins, including uses of these proteins.Type: ApplicationFiled: April 19, 2019Publication date: October 10, 2019Inventors: Marlon Hinner, Andrea Allersdorfer, Rachida Siham Bel Aiba, Michaela Aloe, Alexander Wiedenmann, Gabriele Matschiner, Martin Huelsmeyer
-
Patent number: 10400016Abstract: The present disclosure provides hNGAL muteins that bind CGRP and can be used in various application including pharmaceutical applications, for example, migraine. The present disclosure also concerns methods of making one or more muteins described herein as well as compositions and combinations comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions and combinations comprising one or more of such muteins.Type: GrantFiled: December 7, 2016Date of Patent: September 3, 2019Assignee: PIERIS PHARMACEUTICALS GMBHInventors: Gabriele Matschiner, Christine Rothe, Alexander Wiedenmann, Rachida Siham Bel Aiba, Marlon Hinner, Andrea Allersdorfer, Bradley Lunde, Kazufumi Kubota, Mitsuhiro Makino, Sakiko Takahashi, Ryuji Hashimoto, Tohru Takahashi, Mamoru Otoyo
-
Publication number: 20190240289Abstract: The present invention relates to novel muteins derived from human tear lipocalin, which bind to IL 4 receptor alpha. The sequences of the muteins comprise particular combinations of amino acids. In particular a mutated amino acid residue is present at any one or more of the sequence positions 27, 28 30, 31, 33, 53, 57, 61, 64, 66, 80, 83, 104-106 and 108 of the linear polypeptide sequence of the mature human tear lipocalin. A mutated amino acid residue is also present at any 2 or more of the sequence positions 26, 32, 34, 55, 56, 58 and 63 of the linear polypeptide sequence of the mature human tear lipocalin. The invention also provides a corresponding nucleic acid molecule encoding such a mutein and a method for producing such a mutein and its encoding nucleic acid molecule.Type: ApplicationFiled: January 24, 2019Publication date: August 8, 2019Inventors: Andreas Hohlbaum, Alexandra Baehre, Gabriele Matschiner, Stefan Trentmann, Klaus Kirchfeld, Hans-Juergen Christian
-
Patent number: 10273275Abstract: The present disclosure relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Glypican-3 (GPC3), which proteins preferably are muteins of a lipocalin protein, more preferably of lipocalin 2 (Lcn2 or NGAL). Present disclosure also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, present disclosure also is directed to pharmaceutical and/or diagnostic compositions comprising such lipocalin proteins, including uses of these proteins.Type: GrantFiled: May 18, 2016Date of Patent: April 30, 2019Inventors: Marlon Hinner, Andrea Allersdorfer, Rachida Siham Bel Aiba, Michaela Aloe, Alexander Wiedenmann, Gabriele Matschiner, Martin Huelsmeyer
-
Patent number: 10232014Abstract: The present invention relates to novel muteins derived from human tear lipocalin, which bind to IL 4 receptor alpha. The sequences of the muteins comprise particular combinations of amino acids. In particular a mutated amino acid residue is present at any one or more of the sequence positions 27, 28 30, 31, 33, 53, 57, 61, 64, 66, 80, 83, 104-106 and 108 of the linear polypeptide sequence of the mature human tear lipocalin. A mutated amino acid residue is also present at any 2 or more of the sequence positions 26, 32, 34, 55, 56, 58 and 63 of the linear polypeptide sequence of the mature human tear lipocalin. The invention also provides a corresponding nucleic acid molecule encoding such a mutein and a method for producing such a mutein and its encoding nucleic acid molecule.Type: GrantFiled: June 5, 2017Date of Patent: March 19, 2019Assignees: PIERIS PHARMACEUTICALS GMBH, ASTRAZENECA ABInventors: Andreas Hohlbaum, Alexandra Baehre, Gabriele Matschiner, Stefan Trentmann, Klaus Kirchfeld, Hans-Juergen Christian
-
Publication number: 20180141988Abstract: The present disclosure relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Glypican-3 (GPC3), which proteins preferably are muteins of a lipocalin protein, more preferably of lipocalin 2 (Lcn2 or NGAL). Present disclosure also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, present disclosure also is directed to pharmaceutical and/or diagnostic compositions comprising such lipocalin proteins, including uses of these proteins.Type: ApplicationFiled: May 18, 2016Publication date: May 24, 2018Applicant: Pieris Pharmaceuticals GmbHInventors: Marlon HINNER, Andrea ALLERSDORFER, Rachida Siham BEL AIBA, Michaela ALOE, Alexander WIEDENMANN, Gabriele MATSCHINER, Martin HUELSMEYER
-
Publication number: 20170369542Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Hepcidin, which proteins preferably are muteins of a lipocalin protein. The invention also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, the invention also is directed to pharmaceutical and/or diagnostic compositions comprising such a lipocalin proteins, including uses of these proteins.Type: ApplicationFiled: July 7, 2017Publication date: December 28, 2017Applicant: PIERIS PHARMACEUTICALS GMBHInventors: Stefan TRENTMANN, Gabriele MATSCHINER, Arne SKERRA, Andreas HOHLBAUM, Martin HUELSMEYER, Hendrik GILLE, Hans-Juergen CHRISTIAN, Kristian JENSEN, Rachida Siham BEL AIBA